168 related articles for article (PubMed ID: 32323602)
61. [Myeloproliferative neoplasms - Update on diagnosis and treatment].
Meyer SC; Drexler B; Skoda RC
Ther Umsch; 2019; 76(9):487-495. PubMed ID: 32157965
[TBL] [Abstract][Full Text] [Related]
62. How myeloproliferative neoplasms patients' experience and expectations differ from physicians': the international MPN Landmark survey.
Byun JM; Bang SM; Choi EJ; Eom KS; Jung CW; Kim HS; Park J; Choi CW
Korean J Intern Med; 2022 Mar; 37(2):444-454. PubMed ID: 35272443
[TBL] [Abstract][Full Text] [Related]
63. Management of MPN beyond JAK2.
Harrison CN; Garcia NC
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):348-54. PubMed ID: 25696878
[TBL] [Abstract][Full Text] [Related]
64. Labor market affiliation of patients with myeloproliferative neoplasms: a population-based matched cohort study.
Svingel LS; Christensen SF; Kjærsgaard A; Stenling A; Paulsson B; Andersen CL; Christiansen CF; Stentoft J; Starklint J; Severinsen MT; Borg Clausen M; Hagemann Hilsøe M; Hasselbalch HC; Frederiksen H; Bak M; Mikkelsen EM
Acta Oncol; 2023 Oct; 62(10):1286-1294. PubMed ID: 37656802
[TBL] [Abstract][Full Text] [Related]
65. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms.
Abelsson J; Andréasson B; Samuelsson J; Hultcrantz M; Ejerblad E; Johansson B; Emanuel R; Mesa R; Johansson P
Leuk Lymphoma; 2013 Oct; 54(10):2226-30. PubMed ID: 23398206
[TBL] [Abstract][Full Text] [Related]
66. Leukemic transformation in patients with myeloproliferative neoplasms: a population-based retrospective study.
Shrestha R; Giri S; Armitage JO; Bhatt VR
Future Oncol; 2017 Jun; 13(14):1239-1246. PubMed ID: 28589759
[TBL] [Abstract][Full Text] [Related]
67. Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper.
Barosi G; Vannucchi AM; De Stefano V; Pane F; Passamonti F; Rambaldi A; Saglio G; Barbui T; Tura S
Leuk Res; 2014 Feb; 38(2):155-60. PubMed ID: 24378116
[TBL] [Abstract][Full Text] [Related]
68. Clinical predictors of outcome in MPN.
Passamonti F; Maffioli M; Merli M; Ferrario A; Caramazza D
Hematol Oncol Clin North Am; 2012 Oct; 26(5):1101-16. PubMed ID: 23009940
[TBL] [Abstract][Full Text] [Related]
69. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.
Barbui T; De Stefano V; Alvarez-Larran A; Iurlo A; Masciulli A; Carobbio A; Ghirardi A; Ferrari A; Cancelli V; Elli EM; Andrade-Campos MM; Kabat MG; Kiladjian JJ; Palandri F; Benevolo G; Garcia-Gutierrez V; Fox ML; Foncillas MA; Morcillo CM; Rumi E; Osorio S; Papadopoulos P; Bonifacio M; Cervantes KSQ; Serrano MS; Carreno-Tarragona G; Sobas MA; Lunghi F; Patriarca A; Elorza BN; Angona A; Mazo EM; Koschmieder S; Carli G; Cuevas B; Hernandez-Boluda JC; Abadia EL; Cirici BX; Guglielmelli P; Garrote M; Cattaneo D; Daffini R; Cavalca F; Bellosillo B; Benajiba L; Curto-Garcia N; Bellini M; Betti S; Harrison C; Rambaldi A; Vannucchi AM
Blood Cancer J; 2021 Feb; 11(2):21. PubMed ID: 33563901
[TBL] [Abstract][Full Text] [Related]
70. [Treatment of myeloproliferative neoplasms other than chronic leukemia].
Ohyashiki JH
Nihon Rinsho; 2009 Oct; 67(10):1964-8. PubMed ID: 19860198
[TBL] [Abstract][Full Text] [Related]
71. Thrombosis among 1537 patients with JAK2
Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
[TBL] [Abstract][Full Text] [Related]
72. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map.
Shallis RM; Wang R; Davidoff A; Ma X; Podoltsev NA; Zeidan AM
Blood Rev; 2020 Jul; 42():100706. PubMed ID: 32517877
[TBL] [Abstract][Full Text] [Related]
73. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
74. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
Ruella M; Salmoiraghi S; Risso A; Carobbio A; Buttiglieri S; Spatola T; Sivera P; Ricca I; Barbui T; Tarella C; Rambaldi A
Exp Hematol; 2013 Jul; 41(7):627-34. PubMed ID: 23542632
[TBL] [Abstract][Full Text] [Related]
75. Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event-A population based cohort study.
Larsson AE; Andréasson B; Holmberg H; Liljeholm M; Själander A
Eur J Haematol; 2023 Jun; 110(6):608-617. PubMed ID: 36725666
[TBL] [Abstract][Full Text] [Related]
76. Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.
Alvarez-Larrán A; Pereira A; Magaz M; Hernández-Boluda JC; Garrote M; Cuevas B; Ferrer-Marín F; Gómez-Casares MT; García-Gutiérrez V; Mata-Vázquez MI; Turon F; Hernandez-Gea V; Arellano-Rodrigo E; Cervantes F; García-Pagán JC;
Ann Hematol; 2020 Apr; 99(4):791-798. PubMed ID: 32086587
[TBL] [Abstract][Full Text] [Related]
77. Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.
Kaifie A; Isfort S; Gattermann N; Hollburg W; Klausmann M; Wolf D; Maintz C; Hänel M; Goekkurt E; Göthert JR; Platzbecker U; Geer T; Parmentier S; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
Ann Hematol; 2016 Sep; 95(9):1399-410. PubMed ID: 27334946
[TBL] [Abstract][Full Text] [Related]
78. Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms.
Barzilai M; Kirgner I; Avivi I; Ellis M; Dally N; Rozovski U; Lavi N
Eur J Haematol; 2019 Jun; 102(6):504-508. PubMed ID: 30941804
[TBL] [Abstract][Full Text] [Related]
79. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
80. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.
Gianelli U; Iurlo A; Cattaneo D; Bossi A; Cortinovis I; Augello C; Moro A; Savi F; Castelli R; Brambilla C; Bianchi P; Primignani M; Cortelezzi A; Bosari S
Leuk Res; 2015 May; 39(5):525-9. PubMed ID: 25840747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
